Advent gears up for launch of third life sciences fund

The development comes almost four years after the VC held a final close for ALSF II on £145.5m; the fund received commitments from funds-of-funds, pension funds and family offices.

Advent's life sciences vehicles typically target early- and mid-stage life sciences companies in the UK, continental Europe and the US.

Most recently, Advent Life Sciences took part in a $30m series-C funding round for US-based biotechnology company Aura Biosciences in December 2017 and a $65m series-B for Irish clinical-stage pharmaceutical company Iterum Therapeutics.

Advent had not returned a request for comment at the time of publication.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• UK / Ireland
• Healthcare
• United Kingdom
• Advent Venture Partners